Superior, Non-Opioid Therapy Now Delivered in a Smaller and
More Refined IPG
REDWOOD CITY, California,
Nov. 30, 2017 /PRNewswire/ -- Nevro
Corp. (NYSE:NVRO), a global medical device company that is
providing innovative evidence-based solutions for the treatment of
chronic pain, today announced that it has received CE Mark for its
next-generation Senza II Spinal Cord Stimulation (SCS) System
delivering HF10 therapy. The Senza II system offers the superior
outcomes and clinical advantages of HF10 therapy through a smaller
and more refined footprint while maintaining the performance and
durability of the current Implantable Pulse Generator (IPG).
"My colleagues and I have eagerly awaited the approval of the
Senza II SCS system," said Dr. Adnan
Al-Kaisy, M.D., clinical lead and consultant in the Pain
Management and Neuromodulation department at Guy's and St Thomas'
Hospital in the UK. "The reduced size and optimised design of the
Senza II IPG allow for greater patient comfort and placement
options. This is further advancement of a device that seven years
ago revolutionised treatment for chronic back and pain sufferers by
providing profound and paresthesia-free pain relief."
"Senza II is a step forward that represents our company's
commitment to continuously advancing our product portfolio," said
Rami Elghandour, President and CEO
of Nevro. "The smaller, refined footprint delivers the unparalleled
performance of our current Senza system and is backed by the same
best-in-class clinical evidence that you've come to expect from
Nevro and HF10 therapy. We look forward to initiating a controlled
rollout in Europe."
About the Senza II System and HF10 Therapy
The Senza II system (which is available only in European Economic
Area countries) delivers Nevro's proprietary HF10 therapy, an SCS
therapy that provides electrical pulses to the spinal cord to
alleviate pain. The electrical pulses are delivered by small
electrodes on leads that are placed near the spinal cord and are
connected to a compact, battery-powered generator implanted under
the skin. HF10 therapy is the only SCS therapy indicated to provide
pain relief without paresthesia (a stimulation-induced sensation,
such as tingling or buzzing, which is the basis of traditional SCS)
and is also the first SCS therapy to demonstrate superiority to
traditional SCS for back and leg pain in a comparative pivotal
study. Nevro's innovations in SCS, including the Senza® and Senza
II™ systems and HF10™ therapy, are covered by more than 140 issued
U.S. and international patents.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has
developed and commercialized the Senza spinal cord stimulation
(SCS) system, an evidence-based, non-pharmacologic neuromodulation
platform for the treatment of chronic pain. The Senza system is the
only SCS system that delivers Nevro's proprietary HF10 therapy.
Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of
Nevro.
Investor Relations Contact:
Nevro Investor Relations
Katherine Bock
+1 (650) 433-3247
ir@nevro.com
Logo -
http://mma.prnewswire.com/media/613440/Nevro_logo_R_2016.jpg